Suggested remit: To appraise the clinical and cost effectiveness of glycopyrronium bromide cream within its marketing authorisation for treating severe primary axillary hyperhidrosis.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6487

Provisional Schedule

Committee meeting 08 October 2025
Expected publication 17 December 2025

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Stakeholders

Companies sponsors Leith Healthcare
Others Department of Health and Social Care
  NHS England
Patient carer groups South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups British Association of Dermatologists
  British Dermatological Nursing Group
  Primary Care Dermatology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
Assessment group BMJ Group
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Abbvie (botulinum toxin type A)
  Aspire Pharma (prolonged-release oxybutynin)
  Croma Pharma (botulinum toxin type A)
  Dawa (glycopyrronium bromide)
  Evolus International (botulinum toxin type A)
  Galderma (botulinum toxin type A)
  Grünenthal Meds (propantheline bromide)
  Merz Aesthetics (botulinum toxin type A)
  Morningside Healthcare (glycopyrronium bromide)
  Neon Healthcare (oxybutynin)
  Tillomed laboratories (oxybutynin)
  Strandhaven Limited t/a Somex Pharma (glycopyrronium bromide)
  Strides Pharma (oxybutynin)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups British Skin Foundation
  Cochrane Skin Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
10 March 2025 Invitation to participate
04 February 2025 (00:00) Scoping workshop
05 December 2024 - 14 January 2025 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6487
12 December 2024 Referral
05 December 2024 In progress. Scoping commenced.
16 September 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual